The San Clemente Journal is a quarterly Magazine, published by Community Publications Network since 1995 that is your go-to resource to connect with the people, places, and things that matter most in and around San Clemente, California.

Celebrating Life in San Clemente | Celebrating Life in San Clemente

Huawei Announces Wi-Fi 7 Patent Licensing Rates, Reaffirms Commitment to Transparent and Reasonable Licensing

SHENZHEN, CHINA -  Media OutReach Newswire - 3 July 2026 - Huawei today announced that its patent licensing royalty rate for Wi‑Fi 7 technologies would be set at  US$0.5 per unit for Wi Fi 7 compliant devices. 
       
 This announcement underscores Huawei's dedication to fostering a healthy innovation ecosystem through fair, transparent, and predictable licensing practices. 
  As the latest generation of Wi-Fi technologies, Wi-Fi 7 delivers dramatically higher throughput, lower latency, and greater reliability. Serving as much more than just a connectivity upgrade, it lays the groundwork for the next wave of digital transformation and opens up new possibilities for interactions between people and intelligent systems. 
  As a leading contributor to the IEEE 802.11 standards family, Huawei has played a pivotal role in shaping Wi‑Fi 7 (802.11be) technologies and holds one of the largest portfolios of declared essential patents for Wi‑Fi 7. The company has invested a decade of research and substantial resources into developing the core technologies that make Wi-Fi 7 truly next generation. 
  Huawei has thus emerged as a leader in the global Wi-Fi licensing landscape, and its patent license agreements had covered over 1.2 billion consumer electronic devices worldwide by the end of 2024. 
  With today's announcement, Huawei provides clear advance notice of its Wi‑Fi 7 royalty rate, which is US$0.5 per unit for consumer‑grade Wi‑Fi 7 devices. Implementers may obtain licenses either through bilateral agreements or via patent pools, on FRAND (Fair, Reasonable, and Non-Discriminatory) terms. 
  In July 2022, Huawei joined the Sisvel Wi‑Fi 6 patent pool as a founding member, concurrently becoming both a licensor and a licensee of the pool. The patent pool is a valuable option for the industry which in large provides a "one-stop" licensing solution under a transparent and fair framework with lower transactions costs. 
  Huawei also maintains a strong and proven Wi-Fi 6 patent portfolio, which has been widely recognized and licensed across the industry. This legacy of innovation across successive generations further demonstrates Huawei's long-term commitment to advancing wireless connectivity. 
  Building on this success, Huawei has extended its participation to the Sisvel Wi‑Fi Multimode pool as a founding member, offering licensees a single, streamlined platform for accessing essential patents across both Wi‑Fi 6 and Wi‑Fi 7 generations. 
  Alan Fan, Huawei's Chief Intellectual Property Officer, said: "Through these initiatives, Huawei continues to facilitate collaborative licensing models that balance the interests of innovators and implementers, further reinforcing its leadership in shaping a transparent and efficient global Wi-Fi licensing environment." 
  For more information on Huawei's Wi‑Fi 7 licensing program, please visit  [Huawei IP licensing webpage]. 
 Hashtag: #Huawei 

https://www.huawei.com/za/
https://www.linkedin.com/company/Huawei
https://twitter.com/HuaweiSAR
https://www.facebook.com/HuaweiSAR
http://www.google.com/+Huawei
http://www.youtube.com/Huawei
The issuer is solely responsible for the content of this announcement.

Happy 250th Birthday, America! Salute to Veterans Series shares the stories of veterans during military/patriotic holidays in 2026

Adrift after loss, he built a life — and a blueprint — around purpose

Get more than you expect out of summer road trips by rewarding yourself along the way

4 Tips To Maintain Your Health While Traveling This Summer

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for […]

Greenland Energy (NASDAQ: GLND) Targets Untapped Potential of Jameson Land Basin

Greenland Energy (NASDAQ: GLND) is advancing a significant opportunity in Greenland’s Jameson Land Basin, one of the world’s largest remaining underexplored onshore hydrocarbon regions spanning more than 8,400 square kilometers. Under an agreement with 80 Mile, Greenland Energy will fully fund a two-well drilling program planned for the second half of 2026, earning a 70% interest […]

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial Supply

TAIPEI, TAIWAN -  Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics. 
  With the close of the transaction, Bora Group's biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, and one development facility in Zhubei, Taiwan. 
  "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities." 
  With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK with fully integrated QC and analytical capabilities. 
  Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure. 
  Bora Group intends to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. 
  
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.

About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life. 
  By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries. 
  For more, please visit: 
 https://www.bora-corp.com 
 https://www.boracdmo.com 
  Disclaimer:  
 This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

AITO Retains Top Position in Interbrand’s Luxury NEV Ranking in China for Second Consecutive Year

Consecutive recognition from Interbrand and Brand Finance affirms AITO’s growing brand strength and global standing in the luxury automotive sector CHONGQING, CHINA, 1 JUL 2026 – AITO, the luxury intelligent new energy vehicle (NEV) brand under SERES, has been recognized 12th overall among 60 distinguished brands in the 2025 Brand Momentum Ranking, published by world-renowned […]

New Poll: 80% of Americans Say the Country Isn't Teaching Enough Civics

XTransfer Returns to the Summer Davos Forum

SMEs Serve as a “Buffer” for Globalisation

   HONG KONG SAR -    Media OutReach Newswire - 2 July 2026 -    XTransfer, the World's Leading B2B Cross-Border Trade Payment Platform, attended the    World Economic Forum's 17th Annual Meeting of the New Champions (Summer Davos) in Dalian. Marking a new milestone,    XTransfer has officially become an Institutional Member of the World Economic Forum and is the only institutional member from China's B2B cross-border payments sector. Moving from participant to co-builder, XTransfer joined political and business leaders to discuss transformation in international trade and digital finance.   
   
       
 At the forum,  Bill Deng, XTransfer Founder and CEO, delivered a keynote in the session  "China Platforms Go Global". He described how Chinese e-commerce platforms have evolved from domestic "digital disruptors" to global "rule reshapers" and outlined key obstacles in cross-border payments, including compliance demands, geopolitics, and varying regulatory regimes.  Deng noted that while deglobalization and geopolitical risks can weigh heavily on large enterprises, SMEs tend to be more resilient due to light-asset models and their ability to enter or exit markets quickly. In a fragmented global economy, SMEs can adapt faster, form new connections, and act as a "buffer" that supports stability and deeper global integration. 
  Deng was also invited to attend a closed-door meeting between Chinese Premier Li Qiang and business representatives, as well as multiple closed-door strategic discussions in the financial sector, where views were exchanged on payment risk management, international cooperation, and trends in Chinese companies expanding overseas. 
  Deng shared, "China's expansion is moving from  'trade going global' toward  'ecosystem going global' spanning manufacturing, brands, culture, and financial services, with SMEs playing a central role."  He added that emerging markets are becoming new growth hotspots and urged businesses to leverage supply-chain strengths and move early into markets with strong demand and relatively limited competition. 
  Deng also shared that XTransfer has grown rapidly in recent years, with over 890,000 registered customers, partnerships with more than 170 financial institutions and provides services across 200+ countries and regions. In 2025, the platform processed over US$60 billion TPV, becoming the world's largest B2B cross-border trade payment platform. 
  He emphasised that risk control and compliance are the toughest challenges for cross-border payments. XTransfer's self-developed LLM, TradePilot, has helped keep the fraud rate at 0.003%, among the industry's lowest, enabling SMEs to transact safely, efficiently, and compliantly in global expansion. 
 Hashtag: #XTransfer #summerdavos #WEF #CrossborderPayment

https://www.xtransfer.com
https://www.linkedin.com/company/xtransfer.cn
The issuer is solely responsible for the content of this announcement.

Why ventilation may be the most important feature in your home

250 Years of Service, Reimagined: Meet the Soldiers Who Make Up Today’s Army

Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly […]

Beeline Holdings (NASDAQ: BLNE) Completes MagicBlocks Acquisition

Beeline Holdings (NASDAQ: BLNE) announced the completion of its acquisition of artificial intelligence company MagicBlocks, whose technology powers the company’s proprietary AI agent, Bob, and supports automation across its mortgage origination and title operations. The company said full ownership of the technology is expected to accelerate AI-driven automation, reduce production costs and improve the speed and consistency of the borrower experience. […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is […]

Datavault AI (NASDAQ: DVLT) Plans Strategic Minerals Platform With Patriot Strategic Metals

Datavault AI (NASDAQ: DVLT) announced a proposed strategic partnership with Patriot Strategic Metals LLC to jointly develop the Strategic Materials Acquisition Platform, an institutional digital infrastructure platform designed to support the financing, tokenization, settlement and lifecycle management of strategic mineral assets. The companies said the platform would combine Patriot Strategic Metals’ strategic metals operations with Datavault […]

Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more […]

HeartBeam (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of a healthcare facility. As healthcare increasingly emphasizes earlier intervention and more personalized care,&#160;HeartBeam (NASDAQ: BEAT)&#160; is developing technologies designed to transform where and how cardiac [&#8230;]

Growing Interest From Cryptocurrency Holders Fuels Engagement Across the XRPPower Ecosystem

ROMFORD, England — July 1, 2026 — As the global digital asset industry moves beyond speculative trading, cryptocurrency holders are increasingly exploring platforms that combine blockchain infrastructure with practical technology applications. Against this backdrop, XRPPower, operated by XRP RIPPLE LTD, says it is seeing continued engagement from users seeking AI-powered digital services within an integrated […]